Rigel Pharmaceuticals RIGL Loans Payable, Noncurrent
Loans Payable, Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermLoansPayable.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's loans payable, noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's loans payable, noncurrent?
- Rigel Pharmaceuticals (RIGL) reported loans payable, noncurrent of $14.99M in Q1 2026.
- How has Rigel Pharmaceuticals's loans payable, noncurrent changed year-over-year?
- Rigel Pharmaceuticals's loans payable, noncurrent decreased by 66.6% year-over-year, from $44.93M to $14.99M.
- What is the long-term trend for Rigel Pharmaceuticals's loans payable, noncurrent?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's loans payable, noncurrent has grown at a 2.6% compound annual growth rate (CAGR), from $19.82M to $22.48M.
- What does loans payable, noncurrent mean?
- This represents the total principal amount of debt obligations that are due beyond the next twelve months. It reflects the company's long-term capital structure and its reliance on external financing to fund operations or growth. Investors monitor this to assess the company's leverage profile and the sustainability of its long-term debt burden.